These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Diabetes and cardiovascular risk markers. Erdmann E Curr Med Res Opin; 2005; 21 Suppl 1():S21-8. PubMed ID: 15811196 [TBL] [Abstract][Full Text] [Related]
23. Effects of gliclazide on endothelial function in patients with newly diagnosed type 2 diabetes. Chen LL; Yu F; Zeng TS; Liao YF; Li YM; Ding HC Eur J Pharmacol; 2011 Jun; 659(2-3):296-301. PubMed ID: 21453695 [TBL] [Abstract][Full Text] [Related]
24. Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes. van Genugten RE; Möller-Goede DL; van Raalte DH; Diamant M Diabetes Obes Metab; 2013 Jul; 15(7):593-606. PubMed ID: 23216746 [TBL] [Abstract][Full Text] [Related]
25. PPAR ligands: are they potential agents for cardiovascular disorders? Balakumar P; Rose M; Singh M Pharmacology; 2007; 80(1):1-10. PubMed ID: 17496434 [TBL] [Abstract][Full Text] [Related]
26. Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes. Tandon N; Ali MK; Narayan KM Am J Cardiovasc Drugs; 2012 Feb; 12(1):7-22. PubMed ID: 22217193 [TBL] [Abstract][Full Text] [Related]
30. Impact of 6 weeks of treatment with low-dose metformin and atorvastatin on glucose-induced changes of endothelial function in adults with newly diagnosed type 2 diabetes mellitus: A single-blind study. Tousoulis D; Koniari K; Antoniades C; Miliou A; Noutsou M; Nikolopoulou A; Papageorgiou N; Marinou K; Stefanadi E; Stefanadis C Clin Ther; 2010 Sep; 32(10):1720-8. PubMed ID: 21194594 [TBL] [Abstract][Full Text] [Related]
32. Hypoglycemic pharmacological treatment of type 2 diabetes: targeting the endothelium. Nathanson D; Nyström T Mol Cell Endocrinol; 2009 Jan; 297(1-2):112-26. PubMed ID: 19038307 [TBL] [Abstract][Full Text] [Related]
33. Endothelial dysfunction: how can one intervene at the beginning of the cardiovascular continuum? Schmieder RE J Hypertens Suppl; 2006 Apr; 24(2):S31-5. PubMed ID: 16601559 [TBL] [Abstract][Full Text] [Related]
35. Focus on metformin - a major cardiovascular medication. 'Diabesity - the biggest epidemic in human history'. Straughan JL Cardiovasc J Afr; 2007; 18(5):331-3. PubMed ID: 17985034 [No Abstract] [Full Text] [Related]
36. Endothelial dysfunction and type 2 diabetes. Part 2: altered endothelial function and the effects of treatments in type 2 diabetes mellitus. Guerci B; Böhme P; Kearney-Schwartz A; Zannad F; Drouin P Diabetes Metab; 2001 Sep; 27(4 Pt 1):436-47. PubMed ID: 11547217 [TBL] [Abstract][Full Text] [Related]